President's Address: Parenteral Nutrition Compounding: Advancement or Regression - Where Do We Stand? (SA10)

ASPEN’s 47th president, Phil Ayers, PharmD, BCNSP, FASHP will provide a historical overview of PN compounding and will focus on the question, “Have we progressed or regressed in the area of PN compounding?”

Parenteral nutrition (PN) is a high-alert medication that can cause significant patient harm when they are used in error. An important step in the PN process is compounding. It requires competency in the areas of sterility, stability, and compatibility. Although the actual compounding is executed by the pharmacy, it is imperative that all clinicians involved in the PN process have an understanding of sterile compounding basics.

A recent revision to USP Chapter <797>, effective in November 2023, categorizes sterile compound products (CSPs) based on beyond use dating (BUD) and no longer clearly places PN in a CSP category. This change, along with the increased use of commercially available multi-chamber PN, has presented some confusion among clinicians and could potentially lead to compounding errors and patient harm.

LEARNING OBJECTIVES

1. Summarize sterile compounding basics.
2. Prevent parenteral nutrition compounding errors.

PRESENTER
Phil Ayers, PharmD, BCNSP, FASHP, Chief, Clinical Pharmacy Services, Department of Pharmacy, Mississippi Baptist Medical Center, Jackson, MS

Level: Intermediate